Druckenmiller’s 4Q13 Portfolio Changes
Stan Druckenmiller is a billionaire, and was the long-time manager of Duquesne Capital. Now, he oversees a family office, but his investing strategy is mostly the same.
Posts Tagged ‘Bristol Myers Squibb Co. (BMY)’
Billionaire Stan Druckenmiller’s Top Stock Picks
In a latest 13F filing, Stanley Druckenmiller’s fund Duquesne Capital, revealed its holdings for the fourth quarter of 2013.
The Pharmaceutical Industry’s 10 Biggest R&D Budgets
Innovation is everything when it comes to the pharmaceutical sector.
AstraZeneca plc (ADR) (AZN), Merck & Co., Inc. (MRK), Endocyte, Inc. (ECYT): Three Things You Need to Know About This Big Pharma Deal
Through the years, London-based drugmaker AstraZeneca plc (ADR) (NYSE:AZN) and U.S. pharmaceutical firm Merck & Co., Inc.
Bristol Myers Squibb Co. (BMY), Merck & Co., Inc. (MRK): Is AstraZeneca plc (ADR) (AZN)’s Recent Acquisition Bigger Than Onyx?
AstraZeneca plc (ADR) (NYSE:AZN) may have missed out on acquiring the oncology platform of Onyx Pharmaceuticals, but it responded by pulling the trigger on a $500 million deal...
Celgene Corporation (CELG), Bristol-Myers Squibb Co (BMY): One Drug Dramatically Reshaping Pancreatic Cancer Treatment
A couple months may not seem like a long time, but when you're diagnosed with pancreatic cancer, the prospect of a few months makes a huge difference.
Dividend Stock News: ConocoPhillips (COP) on Hydraulic Fracturing, Intel Corporation (INTC)’s Latest Chips, Bristol-Myers Squibb Co (BMY)’s Study Goal
As the CEO of ConocoPhillips (NYSE:COP), the largest independent oil company in the nation, Ryan Lance was happy to address the pros and cons of hydraulic fracturing - or "fracking...
Do Hedge Funds and Insiders Love AstraZeneca plc (ADR) (AZN)?
At the moment, there are dozens of gauges investors can use to track Mr. Market. A pair of the most under-the-radar are hedge fund and insider trading movement.
Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX), Johnson & Johnson (JNJ): When Will the Good News End for This Biotech?
The big biotech announced on Thursday that updated results from its phase 3 study of Pomalyst in treating relapsed or refractory multiple myeloma had been published online in ...
Astex Pharmaceuticals, Inc. (ASTX) Becomes the Latest Biotech Domino to Fall
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals.
Sanofi SA (ADR) (SNY), Bristol Myers Squibb Co. (BMY): Why Peregrine Pharmaceuticals (PPHM) Earnings Won’t Show Profits
Peregrine Pharmaceuticals (NASDAQ:PPHM) will release its latest quarterly report on Monday, and investors are under no illusions that the company will avoid losing money again...
AstraZeneca plc (ADR) (AZN), Bristol Myers Squibb Co. (BMY), GlaxoSmithKline plc (ADR) (GSK): Diabetes Drugmakers and Their “Definitely Maybe” Moment
Over the past decade, the Food and Drug Administration has taken multiple steps to improve the process by which drugs are developed and eventually brought to market.
This Metric Says You Are Smart to Buy GlaxoSmithKline plc (ADR) (GSK)
In the financial world, there are many methods market participants can use to track the equity markets.
AbbVie Inc (ABBV): Are Hedge Funds Right About This Stock?
Now, according to many investors, hedge funds are seen as overrated, outdated investment tools of a period lost to current times.
AstraZeneca plc (ADR) (AZN), Bristol-Myers Squibb Co (BMY), BioMarin Pharmaceutical Inc. (BMRN): Three PDUFA Dates That Will Kick Off 2014
The phrase "PDUFA date" is thrown around frequently when discussing biotech and pharma companies.
Alkermes Plc (ALKS), Eli Lilly & Co. (LLY), AstraZeneca plc (ADR) (AZN): Tackling Pain and Addiction
Alkermes Plc (NASDAQ:ALKS) is primarily known for its schizophrenia and multiple sclerosis drug treatments.
Curis, Inc. (CRIS), Bristol Myers Squibb Co. (BMY), Novartis AG (ADR) (NVS): Can Stopping This Hedgehog Create New Cancer Treatments?
Curis, Inc. (NASDAQ:CRIS) and Roche Holding Ltd.
Hedge Funds Are Buying Bristol Myers Squibb Co. (BMY)
In the eyes of many of your peers, hedge funds are perceived as useless, outdated financial tools of a forgotten age.
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY), MannKind Corporation (MNKD): Three New Diabetes Drugs Possibly on the Way Soon
It's no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide.
Eli Lilly & Co. (LLY): Cancer Breakthrough Could Mean Big Gains for This Pharma Giant
The battle against cancer is both valiant and frustrating.
A Smart Eli Lilly & Co. (LLY) Investor Does What Now?
Eli Lilly & Co. (NYSE:LLY) was in 35 hedge funds' portfolio at the end of March. LLY investors should be aware of a decrease in hedge fund interest recently.
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Bristol-Myers Squibb Co (BMY), Johnson & Johnson (JNJ): Buy These Leading Pharma Companies
A recent EvaluatePharma report estimated the market for prescribed drugs will increase at an annual rate of 3.8% to $895 billion from 2012 to 2018.
Eli Lilly & Co. (LLY), Merck & Co., Inc. (MRK), Allergan, Inc. (AGN): Three Companies Working to Make Your Migraines Milder
The National Headache Foundation (yes, there is such an organization) says that around 30 million Americans suffer from migraines.
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Bristol-Myers Squibb Co (BMY): These Pharmaceutical Giants Are Teetering Dangerously Near The Patent Cliff
In the hunt for sustainable dividend yields, investors have rushed into the stocks of major pharmaceutical companies.
3 Things You Need to Know From Vical Incorporated (VICL)’s Q2 Results
Vical Incorporated (NASDAQ:VICL) announced its second-quarter results on Thursday.
Vertex Pharmaceuticals Incorporated (VRTX): This Biotech’s Cystic Fibrosis Treatments Could Catapult It To Profitability
Cystic fibrosis (CF), a genetic disorder that affects the lungs, the pancreas, liver, and intestine, is the second most common inherited disorder in the United States, after sickle...
Three Things You Need to Know From Merck & Co., Inc. (MRK)’s Q2 Earnings
The good news was that the big pharmaceutical company beat earnings estimates. Merck & Co., Inc.
AstraZeneca plc (ADR) (AZN) and Bristol Myers Squibb Co. (BMY): 2 Keys to Success for This Diabetes Drug’s Second Chance
AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) announced last week that they are making another attempt at U.S.
Bristol Myers Squibb Co. (BMY), AstraZeneca plc (ADR) (AZN): Expanding P/E Saved This Pharma Investment
Three years ago, the company told investors not to worry. It had a plan to replace the $6 billion drug that lost patent protection last year.
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY): The Diabetes Pipeline With a Clog
Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE:JNJ), Eli Lilly & Co.
Bristol Myers Squibb Co. (BMY), Gilead Sciences, Inc. (GILD): Did Someone Just Cure AIDS for $200,000?
According to multiple reports , Harvard researchers Timothy Henrich and Daniel Kuritzkes have recently noted a surprising side-effect to cancer treatments performed on two separate...
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): The Five Most Misdiagnosed Diseases
There's little denying that the technological, research, and medicinal aspects of patient care are improving at breakneck speed.
Gilead Sciences, Inc. (GILD), AbbVie Inc (ABBV), Bristol Myers Squibb Co. (BMY): Three Future Winners and One Major Loser in the HCV Wars
The biotech industry is a cutthroat one, with companies constantly racing to get new treatments approved by the FDA ahead of their rivals.
Four Potential Suitors for Onyx Pharmaceuticals, Inc. (ONXX)
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX): A Fundamentally Strong Biotech Stock
Celgene Corporation (NASDAQ:CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed that it could be an initial...
VIVUS, Inc. (VVUS), Merck & Co., Inc. (MRK): What’s Your Biggest Fear? The Answer Might Scare You!
With all of the factors we have to worry about in our everyday lives, it is somewhat a wonder that we're not only able to survive, but thrive, as a society.
Eli Lilly & Co. (LLY), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): The 3 Most Commonly Diagnosed Mental Disorders
The medical community certainly spends a lot of time and money researching treatments for cardiovascular disease and cancer.
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Revlimid Results Rev Up Celgene Corporation (CELG)
Good news seems to find its way to Celgene Corporation (NASDAQ:CELG)'s door frequently these days.
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Gilead Sciences, Inc. (GILD), Johnson & Johnson (JNJ): Is a Breakthrough Treatment on the Way for People With HIV?
We as a country have a come a long way over the past two decades with regard to treating HIV and reducing the number of AIDS diagnoses.
The Medicines Company (MDCO), AstraZeneca plc (ADR) (AZN): A Small-Cap Pharmaceutical Company With 2014 in Its Sights
A few months back, Barron's featured an intriguing pharmaceutical company that goes by the name The Medicines Company (NASDAQ:MDCO).
How Much Is Onyx Pharmaceuticals, Inc. (ONXX) Really Worth?
The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close.
Johnson & Johnson (JNJ), Bristol Myers Squibb Co. (BMY): Top Dividend Stocks in Big Pharma
When looking for the best dividend stocks, it's usually best to not chase the highest dividend.
Amgen, Inc. (AMGN) vs. Big Pharma: It’s Amgen for the Long Term
Over the last three decades I have seen my share of bull and bear markets.
Is Now a Good Time to Buy Merck & Co., Inc. (MRK) Stock?
Merck & Co., Inc. (NYSE:MRK) has had its fair share of bad news recently. Shares have pulled back around 5% in June.
GlaxoSmithKline plc (ADR) (GSK), Bristol Myers Squibb Co. (BMY), Merck & Co., Inc. (MRK): If You Are an Income Investor, You Will Love These Pharma Companies
Companies know that to attract regular income-seeking investors, it helps to pay out high dividends.
